Custom Award recognizing contributions to the development of a medical implant, and embedding the actual device within Lucite. (23AZH106)
Custom Award recognizing contributions to the development of a medical implant, and embedding the actual device within Lucite. (23AZH106)
Lucite commemorative marking the first patient dosed in a clinical study involving LunAIRo. Developed by Apnimed, the drug is intended for the treatment of obstructive sleep apnea. (23AZH173)
Diamond-shaped crystal deal toy commemorating a follow-on stock offering by Swiss biotech firm Oculis. (23AKL262)
Logo-themed Lucite tombstone celebrating Series B funding for Carta Healthcare. The San Francisco-based company provides a patient management platform for hospitals that makes use of artificial intelligence (AI). (23AZH141)
Custom Lucite with an embedded drug vial commemorating FDA approval of ELAHERE. Developed by ImmunoGen, the drug was granted accelerated FDA approval as a treatment for ovarian cancer. (23AKL266)
Logo-themed deal toy, incorporating spheres with logos, marking the acquisition of medical advocacy service provider MAP Health. The acquirer was Louisville, Kentucky-based health management software company SentryHealth. (23AKL284)
Crystal deal toy commemorating the acquisition of PharmaSmart, a Rochester, New York-based provider of healthcare screening kiosks. The acquirer was Canadian private equity firm CPS Capital. (23AKL282)
Lucite tombstone recognizing a registered direct offering by BioCardia. The Sunnyvale, California-based company develops cellular and cell-derived therapeutics for cardiovascular and pulmonary conditions. (23AKL286)
Crystal commemorative marking a licensing and commercialization agreement between Corbus Pharmaceuticals and CSPC Pharmaceutical Group. The agreement centers on a potential treatment for tumors associated with lung, breast, and prostate cancers. (23AZH089)
